In addition to direct regulation of key metabolic checkpoints, AMPK may also inhibit tumorigenesis through upregulation of transcription factors such as the tumor suppressor p53, which is mutated in approximately 80% of all cancers (He et al., 2014; Jones et al., 2005; Lee et al., 2012). Here, TP53 is linked to cancer.